Drugs / Nevanimibe
Nevanimibe
also known as
ATR-101 · Nevanimibe HCl · ATR-101 FREE BASE · ATR-101 HYDROCHLORIDE · Nevanimiba · nevanimibe hydrochloride · PD 132301 · PD 132301-02 · +2 more
Small molecule targets SOAT1 via inhibition
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01898715 | Aug 2013 → Nov 2016 | adrenal cortex carcinoma | Millendo Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT03669549 | Jul 2018 → Jun 2020 | congenital adrenal hyperplasia | Millendo Therapeutics US, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT03053271 | Apr 2017 → Jun 2019 | endogenous Cushing syndrome | Millendo Therapeutics US, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02804178 | May 2016 → Aug 2017 | congenital adrenal hyperplasia | Millendo Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nevanimibe | “Nevanimibe hydrochloride (ATR-101), which selectively inhibits adrenal cortex function, might reduce androgen excess independent of ACTH and thus allow for lower glucocorticoid...” PMID 32589738 ↗ Aug 20202“Nevanimibe HCl (formerly ATR-101), a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor” PMID 31984451 ↗ Jan 2020 |
| Known as | ATR-101 | “Nevanimibe HCl (formerly ATR-101), a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor” PMID 31984451 ↗ Jan 2020 |
| Known as | ATR-101 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL46423 ↗ |
| Known as | ATR-101 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL46423 ↗ |
| Known as | Nevanimiba | ChEMBL registry synonym — accepted as the source's own label CHEMBL46423 ↗ |
| Known as | Nevanimibe HCl | “During the 16-week treatment period, all subjects will begin dosing with nevanimibe HCl 500 mg BID and be dose titrated to 1000 mg BID, 1500 mg BID, and 2000 mg BID as needed...” NCT03669549 ↗1“Nevanimibe HCl (formerly ATR-101), a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor” PMID 31984451 ↗ Jan 2020 |
| Known as | nevanimibe hydrochloride | “This is a multicenter, intra-subject dose-titration open-label study of nevanimibe hydrochloride (HCl) for the treatment of classic congenital adrenal hyperplasia (CAH).” NCT03669549 ↗ |
| Known as | PD 132301 | ChEMBL registry synonym — accepted as the source's own label CHEMBL46423 ↗ |
| Known as | PD 132301-02 | ChEMBL registry synonym — accepted as the source's own label CHEMBL46423 ↗ |
| Known as | PD-132301 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL46423 ↗ |
| Known as | PD-132301-2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL46423 ↗ |
| Action | Inhibit | “a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor” PMID 31984451 ↗ Jan 2020 |
| Modality | Small molecule | — CHEMBL46423 ↗ |
| Route | Oral | “dosed with oral nevanimibe” PMID 31984451 ↗ Jan 2020 |
| Target | SOAT1 | “a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor” PMID 31984451 ↗ Jan 2020 |